Lymphocyte activation gene 3 protein · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Lymphocyte activation gene 3 protein shows late clinical disease relevance led by melanoma. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P18627. Start with melanoma, then reuse UniProt P18627 as the stable protein anchor across project notes and exports.
Start with melanoma, then reuse UniProt P18627 as the stable protein anchor across project notes and exports.
Lymphocyte activation gene 3 protein shows late clinical disease relevance led by melanoma. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with melanoma because it currently carries late clinical support. Linked drugs include EFTILAGIMOD ALFA, FAVEZELIMAB, FIANLIMAB, IERAMILIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyLymphocyte activation gene 3 protein
Review this target as Lymphocyte activation gene 3 protein, mapped to UniProt P18627. Sequence length is 525 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Lymphocyte activation gene 3 protein as ChEMBL target CHEMBL4630881, mapped to UniProt P18627. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Lymphocyte activation gene 3 protein is the right protein anchor across sources, using UniProt P18627 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why melanoma is currently framed as late clinical support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Lymphocyte activation gene 3 protein |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P18627 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Lymphocyte activation gene 3 protein |
| UniProt Accession | P18627 |
| Component Type | Protein |
| Sequence Length | 525 aa |
Lymphocyte activation gene 3 protein
Review this target as Lymphocyte activation gene 3 protein, mapped to UniProt P18627. Sequence length is 525 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Lymphocyte activation gene 3 protein shows late clinical disease relevance led by melanoma. 5 more disease programs remain visible in the same review block.
Start review with melanoma because it currently carries late clinical support. Linked drugs include EFTILAGIMOD ALFA, FAVEZELIMAB, FIANLIMAB, IERAMILIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1 | 0 | — |